Breast cancer in situ

References

Key articles

Virnig BA, Tuttle TM, Shamliyan T, et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010 Feb 3;102(3):170-8.Full text  Abstract

US Preventive Services Task Force. Final recommendation statement: breast cancer screening. February 2016 [internet publication].Full text

Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013 Jun 4;(6):CD001877.Full text  Abstract

Dunne C, Burke JP, Morrow M, et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009 Apr 1;27(10):1615-20. Abstract

Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016 Feb 27;387(10021):849-56. Abstract

Reference articles

1. Hieken TJ, Cheregi J, Farolan M, et al. Predicting relapse in ductal carcinoma in situ patients: an analysis of biologic markers with long-term follow-up. Am J Surg. 2007;194:504-506. Abstract

2. Cocquyt V, Van Belle S. Lobular carcinoma in situ and invasive lobular cancer of the breast. Curr Opin Obstet Gynecol. 2005 Feb;17(1):55-60. Abstract

3. Ginter PS, D'Alfonso TM. Current concepts in diagnosis, molecular features, and management of lobular carcinoma in situ of the breast with a discussion of morphologic variants. Arch Pathol Lab Med. 2017 Dec;141(12):1668-78.Full text  Abstract

4. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004 Jun 16;96(12):906-20.Full text  Abstract

5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30.Full text  Abstract

6. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004 Jun 16;96(12):906-20.Full text  Abstract

7. Portschy PR, Marmor S, Nzara R, et al. Trends in incidence and management of lobular carcinoma in situ: a population-based analysis. Ann Surg Oncol. 2013 Oct;20(10):3240-6.Full text  Abstract

8. Camus MG, Joshi MG, Mackarem G, et al. Ductal carcinoma in situ of the male breast. Cancer. 1994 Aug 15;74(4):1289-93. Abstract

9. Virnig BA, Tuttle TM, Shamliyan T, et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010 Feb 3;102(3):170-8.Full text  Abstract

10. Li CI, Anderson BO, Daling JR, et al. Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res Treat. 2002 Oct;75(3):259-68. Abstract

11. Dania V, Liu Y, Ademuyiwa F, et al. Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ. Breast Cancer Res. 2019 Nov 14;21(1):120.Full text  Abstract

12. Zygogianni AG, Kyrgias G, Gennatas C, et al. Male breast carcinoma: epidemiology, risk factors and current therapeutic approaches. Asian Pac J Cancer Prev. 2012;13(1):15-9. Abstract

13. San Miguel P, Sancho M, Enriquez JL, et al. Lobular carcinoma of the male breast associated with the use of cimetidine. Virchows Arch. 1997 Mar;430(3):261-3. Abstract

14. Olivotto I, Levine M; Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update). CMAJ. 2001;165:912-913.Full text  Abstract

15. Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol. 1999;187:272-278. Abstract

16. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988;319:1239-1245. Abstract

17. Wren BG. The origin of breast cancer. Menopause. 2007;14:1060-1068. Abstract

18. Claus EB, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst. 2001 Dec 5;93(23):1811-7.Full text  Abstract

19. White E, Lee CY, Kristal AR. Evaluation of the increase in breast cancer incidence in relation to mammography use. J Natl Cancer Inst. 1990 Oct 3;82(19):1546-52. Abstract

20. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017 Jun 20;317(23):2402-16.Full text  Abstract

21. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998 Mar;62(3):676-89.Full text  Abstract

22. Birch JM, Blair V, Kelsey AM, et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene. 1998 Sep 3;17(9):1061-8. Abstract

23. Brownstein MH, Wolf M, Bikowski JB. Cowden's disease: a cutaneous marker of breast cancer. Cancer. 1978 Jun;41(6):2393-8. Abstract

24. Pharoah PD, Guilford P, Caldas C, et al. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001 Dec;121(6):1348-53.Full text  Abstract

25. Boardman LA, Thibodeau SN, Schaid DJ, et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med. 1998 Jun 1;128(11):896-9. Abstract

26. Vasen HF. Clinical diagnosis and management of hereditary colorectal cancer syndromes. J Clin Oncol. 2000 Nov 1;18(21 Suppl):81S-92S. Abstract

27. US National Library of Medicine. STK11 gene. 3 March 2020 [internet publication].Full text

28. Jackson AW, Muldal S, Ockey CH, et al. Carcinoma of male breast in association with the Klinefelter syndrome. Br Med J. 1965 Jan 23;1(5429):223-5.Full text  Abstract

29. Patel AV, Press MF, Meeske K, et al. Lifetime recreational exercise activity and risk of breast carcinoma in situ. Cancer. 2003 Nov 15;98(10):2161-9. Abstract

30. Trentham-Dietz A, Newcomb PA, Storer BE, et al. Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2000 Jul;9(7):697-703.Full text  Abstract

31. Izatt L, Greenman J, Hodgson S, et al. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosomes Cancer. 1999 Dec;26(4):286-94. Abstract

32. FitzGerald MG, Bean JM, Hegde SR, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet. 1997 Mar;15(3):307-10. Abstract

33. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer risk reduction [internet publication].Full text

34. Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013 Aug 10;31(23):2942-62.Full text  Abstract

35. Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol. 2019 Nov 20;37(33):3152-65.Full text  Abstract

36. Owens DK, Davidson KW, et al; US Preventive Services Task Force. Medication use to reduce risk of breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2019 Sep 3;322(9):857-67.Full text  Abstract

37. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001 Jul 19;345(3):159-64.Full text  Abstract

38. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86. Abstract

39. National Cancer Institute. Breast cancer risk assessment tool: about the calculator. December 2017 [internet publication].Full text

40. Hankinson SE, Colditz GA, Willett WC. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res. 2004;6(5):213-8.Full text  Abstract

41. Chlebowski RT, Aragaki AK, Anderson GL, et al. Low-fat dietary pattern and breast cancer mortality in the Women's Health Initiative randomized controlled trial. J Clin Oncol. 2017 Sep 1;35(25):2919-26. Abstract

42. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA. 1998 Feb 18;279(7):535-40.Full text  Abstract

43. Sinclair J, McCann M, Sheldon E, et al. The acceptability of addressing alcohol consumption as a modifiable risk factor for breast cancer: a mixed method study within breast screening services and symptomatic breast clinics. BMJ Open. 2019 Jun 17;9(6):e027371.Full text  Abstract

44. Cutuli B, Dilhuydy JM, De Lafontan B, et al. Ductal carcinoma in situ of the male breast: analysis of 31 cases. Eur J Cancer. 1997 Jan;33(1):35-8. Abstract

45. Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010 Jan;7(1):18-27. Abstract

46. Expert Panel on Breast Imaging, Weinstein SP, Slanetz PJ, et al. ACR Appropriateness Criteria® Supplemental Breast Cancer Screening Based on Breast Density. J Am Coll Radiol. 2021 Nov;18(11s):S456-S473.Full text  Abstract

47. Oeffinger KC, Fontham ET, Etzioni R, et al; American Cancer Society. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015 Oct 20;314(15):1599-614.Full text  Abstract

48. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 Aug 1;30(8):1194-1220.Full text  Abstract

49. American Cancer Society. Recommendations for the Early Detection of Breast Cancer. Apr 2021 [internet publication].Full text

50. Peters NH, van Esser S, van den Bosch MA, et al. Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET - randomised controlled trial. Eur J Cancer. 2011 Apr;47(6):879-86. Abstract

51. Fancellu A, Turner RM, Dixon JM, et al. Meta-analysis of the effect of preoperative breast MRI on the surgical management of ductal carcinoma in situ. Br J Surg. 2015 Jul;102(8):883-93. Abstract

52. van Bekkum S, Ter Braak BPM, Plaisier PW, et al. Preoperative breast MRI in management of patients with needle biopsy-proven ductal carcinoma in situ (DCIS). Eur J Surg Oncol. 2020 Oct;46(10 pt a):1854-1860.Full text  Abstract

53. Plana MN, Carreira C, Muriel A, et al. Magnetic resonance imaging in the preoperative assessment of patients with primary breast cancer: systematic review of diagnostic accuracy and meta-analysis. Eur Radiol. 2012 Jan;22(1):26-38. Abstract

54. Hussain M, Cunnick GH. Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast: a review. Eur J Surg Oncol. 2011 Apr;37(4):279-89. Abstract

55. Bruening W, Fontanarosa J, Tipton K, et al. Systematic review: comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions. Ann Intern Med. 2010 Feb 16;152(4):238-46. Abstract

56. Sauter ER, Ross E, Daly M, et al. Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br J Cancer. 1997;76(4):494-501. Abstract

57. Moran CJ, Kell MR, Flanagan FL, et al. Role of sentinel lymph node biopsy in high-risk ductal carcinoma in situ patients. Am J Surg. 2007 Aug;194(2):172-5. Abstract

58. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer [internet publication].Full text

59. Hammond ME, Hayes DF, Wolff AC, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010 Jul;6(4):195-7.Full text  Abstract

60. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian, and pancreatic [internet publication].Full text

61. Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019 Oct;26(10):3025-31.Full text  Abstract

62. Owens DK, Davidson KW, et al; US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement. JAMA. 2019 Aug 20;322(7):652-65.Full text  Abstract

63. US Preventive Services Task Force. Final recommendation statement: breast cancer screening. February 2016 [internet publication].Full text

64. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis [internet publication].Full text

65. National Institute for Health and Care Excellence. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. June 2013 [internet publication].Full text

66. Franceschi D, Crowe J, Zollinger R, et al. Breast biopsy for calcifications in nonpalpable breast lesions. A prospective study. Arch Surg. 1990;125:170-173. Abstract

67. Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg. 2003;186:337-343. Abstract

68. Claus EB. Risk models used to counsel women for breast and ovarian cancer: a guide for clinicians. Fam Cancer. 2001;1:197-206. Abstract

69. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013 Jun 4;(6):CD001877.Full text  Abstract

70. American College of Obstetricians and Gynecologists. Practice bulletin number 179: breast cancer risk assessment and screening in average-risk women. Obstet Gynecol. 2017 Jul;130(1):e1-16. Abstract

71. National Institute for Health and Care Excellence. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. November 2019 [internet publication].Full text

72. Kerlikowske K, Sprague BL, Tosteson ANA, et al. Strategies to identify women at high risk of advanced breast cancer during routine screening for discussion of supplemental imaging. JAMA Intern Med. 2019 Jul 1 [epub ahead of print].Full text  Abstract

73. Narod SA, Iqbal J, Giannakeas V, et al. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 2015 Oct;1(7):888-96. Abstract

74. Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Pract Radiat Oncol. 2016 Sep-Oct;6(5):287-95.Full text  Abstract

75. Shelley W, McCready D, Holloway C, et al; Cancer Care Ontario. Management of ductal carcinoma in situ of the breast. 2018 [internet publication].Full text

76. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009 Nov 10;27(32):5319-24.Full text  Abstract

77. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999 May 13;340(19):1455-61.Full text  Abstract

78. Scalliet PG, Kirkove C. Breast cancer in elderly women: can radiotherapy be omitted? Eur J Cancer. 2007 Oct;43(15):2264-9. Abstract

79. Fisher B, Redmond C, Poisson R, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989 Mar 30;320(13):822-8. Abstract

80. Dunne C, Burke JP, Morrow M, et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009 Apr 1;27(10):1615-20. Abstract

81. McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015 Mar 1;33(7):709-15.Full text  Abstract

82. Moran MS, Zhao Y, Ma S, et al. Association of radiotherapy boost for ductal carcinoma in situ with local control after whole-breast radiotherapy. JAMA Oncol. 2017 Aug 1;3(8):1060-8.Full text  Abstract

83. ClinicalTrials.gov. Radiation therapy in treating women with early stage breast cancer. August 2019 [internet publication].Full text

84. ClinicalTrials.gov. Radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (DCIS). December 2019 [internet publication]Full text

85. Kirby AM. Updated ASTRO guidelines on accelerated partial breast irradiation (APBI): to whom can we offer APBI outside a clinical trial? Br J Radiol. 2018 May;91(1085):20170565.Full text  Abstract

86. Fisher ER, Sass R, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DCIS). Cancer. 1986;57:197-208. Abstract

87. Moran MS, Bai HX, Harris EE, et al. ACR appropriateness criteria(®) ductal carcinoma in situ. Breast J. 2012;18:8-15. Abstract

88. Fung E, Hendry J. External beam radiotherapy (EBRT) techniques used in breast cancer treatment to reduce cardiac exposure. Radiography. 2013;19:73-78.Full text

89. Correa C, Harris EE, Leonardi MC, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017 Mar - Apr;7(2):73-9.Full text  Abstract

90. Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019 Dec 14;394(10215):2165-72.Full text  Abstract

91. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013 Mar 14;368(11):987-98.Full text  Abstract

92. Sundara Rajan S, Verma R, Shaaban AM, et al. Palpable ductal carcinoma in situ: analysis of radiological and histological features of a large series with 5-year follow-up. Clin Breast Cancer. 2013 Dec;13(6):486-91.Full text  Abstract

93. Cutuli B, Dilhuydy JM, De Lafontan B, et al. Ductal carcinoma in situ of the male breast: analysis of 31 cases. Eur J Cancer. 1997 Jan;33(1):35-8. Abstract

94. Godat LN, Horton JK, Shen P, et al. Recurrence after mastectomy for ductal carcinoma in situ. Am Surg. 2009 Jul;75(7):592-5; discussion 595-7. Abstract

95. Hwang ES. The impact of surgery on ductal carcinoma in situ outcomes: the use of mastectomy. J Natl Cancer Inst Monogr. 2010;2010(41):197-9.Full text  Abstract

96. Moran CJ, Kell MR, Flanagan FL, et al. Role of sentinel lymph node biopsy in high-risk ductal carcinoma in situ patients. Am J Surg. 2007 Aug;194(2):172-5. Abstract

97. Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev. 2012 Oct 17;(10):CD007847.Full text  Abstract

98. Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016 Feb 27;387(10021):849-56. Abstract

99. Biganzoli L, Wildiers H, Oakman C, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 2012 Apr;13(4):e148-60. Abstract

100. Petrelli F, Barni S. Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials. Radiother Oncol. 2011 Aug;100(2):195-9. Abstract

101. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006 Nov;42(17):2909-13.Full text  Abstract

102. Bevers TB, Armstrong DK, Arun B, Carlson RW, et al. Breast cancer risk reduction. J Natl Compr Canc Netw. 2010 Oct;8(10):1112-46. Abstract

103. Benitez PR, Keisch ME, Vicini F, et al. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg. 2007 Oct;194(4):456-62. Abstract

104. Godat LN, Horton JK, Shen P, et al. Recurrence after mastectomy for ductal carcinoma in situ. Am Surg. 2009 Jul;75(7):592-5; discussion 595-7. Abstract

105. ClinicalTrials.gov. Radiation therapy with or without trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy. May 2018 [internet publication].Full text

106. Visser LL, Groen EJ, van Leeuwen FE, et al. Predictors of an invasive breast cancer recurrence after DCIS: a systematic review and meta-analyses. Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):835-45.Full text  Abstract

107. Rowell NP. Are mastectomy resection margins of clinical relevance? A systematic review. Breast. 2010;19:14-22. Abstract

108. Rosso S, Gondos A, Zanetti R, et al. Up-to-date estimates of breast cancer survival for the years 2000-2004 in 11 European countries: the role of screening and a comparison with data from the United States. Eur J Cancer. 2010;46:3351-3357. Abstract

109. Pappo I, Wasserman I, Halevy A. Ductal carcinoma in situ of the breast in men: a review. Clin Breast Cancer. 2005;6:310-314. Abstract

110. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88. Abstract

111. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006 Nov;42(17):2909-13.Full text  Abstract

112. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013 Mar 9;381(9869):805-16.Full text  Abstract

113. Kelley BP, Valero V, Yi M, et al. Tamoxifen increases the risk of microvascular flap complications in patients undergoing microvascular breast reconstruction. Plast Reconstr Surg. 2012 Feb;129(2):305-14.Full text  Abstract

114. Zhao X, Liu L, Li K, et al. Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis. Onco Targets Ther. 2015;8:2721-30.Full text  Abstract

115. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751-1761.Full text  Abstract

Use of this content is subject to our disclaimer